Genmab is pulling the plug on an antibody-drug conjugate it had been developing for solid tumors after it missed the mark in early-phase trials.

A phase 2a clinical trial of Urovant’s vibegron in irritable bowel syndrome (IBS) patients has missed its primary endpoint. The setback dents Urovant’s prospects in one indication but still leaves it set up to win approval in overactive bladder and be acquired by Sumitovant Biopharma.

A month after seeing a “robust immune response” from a clutch of respiratory syncytial virus (RSV) vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test for the infectious respiratory disease.

Immunocore’s tebentafusp has improved overall survival in metastatic uveal melanoma patients. The phase 3 success marks a landmark for the use of T-cell receptor (TCR) therapeutics and bispecifics in solid tumors.

Hologic has received a new FDA approval for its HIV test, allowing it to be used simultaneously to both diagnose infections and measure viral load.

Breast cancer diagnostic developer Agendia announced plans to integrate its genomic tests with Paige’s artificial-intelligence-powered pathology services with the goal of building a new digital precision oncology platform.

Like AstraZeneca, Bayer and Sanofi before it, Bristol Myers Squibb has now tapped molecule modeler Schrödinger for a drug discovery collaboration spanning multiple disease areas.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use, combining it with a digital platform that aims to help patients with kidney disease manage their care remotely.

The U.S. Food and Drug Administration (FDA) has accepted ADC Therapeutics’ Biologics License Application (BLA) and granted priority review for the company’s relapsed/refractory diffuse large B-cell lymphoma (DLBCL) treatment, loncastuximab tesirine (Lonca), bringing the drug one step closer to a population in need to additional therapeutic options to manage their disease.

CAMBRIDGE, Mass. — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will participate in a virtual fire side chat at the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:55 a.m. ET.